Ace Inhibitor

About one third of adults with diabetes has chronic kidney disease, making early detection and treatment of CKD important for improving health outcomes. However, many won’t know they have the disease until it has progressed.

In a cohort of patients with COVID-19, along with those at high risk for COVID-19, CV drug use was not associated with poor clinical outcomes, researchers reported.

Older age, obesity, cardiovascular disease, and pre-hospitalization use of steroids and SGLT2 inhibitors are among the factors that increase the risk for severe COVID-19 for people with diabetes, according to a speaker.

Lower angiotensin-converting enzyme messenger RNA and protein levels were associated with increased schizophrenia risk, according to results of a Mendelian randomization study published in JAMA Psychiatry.

Use of ACE inhibitors and angiotensin receptor blockers was not associated with an increased rate of COVID-19 infection or mortality, according to two meta-analyses reported at the virtual American Heart Association Scientific Sessions.

Impact on days alive and out of hospital from suspending orcontinuing ACE inhibitors and angiotensin receptor blockers for COVID-19.

The European Society of Cardiology Congress was, for the first time, held virtually. From Aug. 29 to Sept. 1, the digital experience drew virtual attendees from around the world, to watch and hear the latest on topics ranging from the benefits of SGLT2 inhibition in patients without diabetes to the first randomized trial on the question of whether to stop ACE inhibitors and angiotensin receptor blockers in patients with COVID-19.

Adding low-dose colchicine to medical therapy reduced the risk for cardiovascular events among patients with chronic coronary disease, according to results of the LoDoCo2 trial. It was the top story in cardiology.

In patients hospitalized with mild or moderate COVID-19, suspending ACE inhibitors and angiotensin receptor blockers for 30 days, compared with continued treatment, did not impact the number of days alive and out of hospital.

Use of renin-angiotensin-aldosterone system, or RAAS, antagonists such as ACE inhibitors or angiotensin receptor blockers was linked to reduced risk for colorectal cancer in the 3 years after an index colonoscopy with negative diagnosis.